[HTML][HTML] The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen, WL Chen, KY Lin… - Scientific reports, 2022 - nature.com
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen… - Scientific …, 2022 - researchoutput.ncku.edu.tw
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen… - Scientific …, 2022 - ui.adsabs.harvard.edu
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen… - Scientific …, 2022 - pubmed.ncbi.nlm.nih.gov
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
PL Su, JY Chen, CY Chu, YL Chen… - Scientific …, 2022 - search.ebscohost.com
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
[PDF][PDF] The impact of driver mutation on the treatment outcome of early‑stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen, WL Chen… - Scientific …, 2022 - sabinai-neji.com
Results Patients. A total of 23 patients were enrolled, including 11 and 12 patients received
neoadjuvant pembrolizumab and chemotherapy (combination group) and neoadjuvant …
neoadjuvant pembrolizumab and chemotherapy (combination group) and neoadjuvant …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
PL Su, JY Chen, CY Chu, YL Chen, WL Chen… - Scientific …, 2022 - europepmc.org
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
[HTML][HTML] The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen, WL Chen… - Scientific …, 2022 - ncbi.nlm.nih.gov
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
PL Su, JY Chen, CY Chu, YL Chen, WL Chen… - Scientific …, 2022 - europepmc.org
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …